MannKind Corporation acquisition of scPharmaceuticals Inc.

MannKind Corporation completed its acquisition of scPharmaceuticals Inc. on 2025-10-07, according to the Form 8-K scPharmaceuticals Inc. filed with the SEC on 2025-10-07. The filing's Item 2.01 states no aggregate dollar price. scPharmaceuticals Inc. filed the report because the deal made it part of MannKind Corporation.

Want the whole picture on MannKind Corporation?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on MannKind Corporation: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on MannKind Corporation covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

What the filing says

Parent completed the acquisition of the Company on October 7, 2025 (the " Closing Date "), by causing Purchaser to merge with and into the Company (the " Merger ") pursuant to the Merger Agreement without any action by the Company stockholders in accordance with Section 251(h) of the DGCL.

More from the filing

As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (" SEC ") by scPharmaceuticals Inc., a Delaware corporation (the " Company "), on August 25, 2025, the Company entered into an Agreement and Plan of Merger (the " Merger Agreement "), dated as of August 24, 2025, with MannKind Corporation, a Delaware corporation (" Parent ") and Seacoast Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (" Purchaser ").

Pursuant to the Merger Agreement, on September 8, 2025, Parent, through Purchaser, commenced a tender offer to purchase all the outstanding shares of the Company's common stock, par value $0.0001 per share (the " Shares "), at a price per Share of (i) $5.35 in cash (the " Cash Amount "), without interest, subject to any applicable withholding taxes and (ii) one non-tradable contingent value right (each, a " CVR ") per Share, which represents the right to receive certain contingent payments of up to an aggregate amount of $1.00 per CVR in cash, without interest, subject to any applicable withho

At the effective time of the Merger (as defined below) (the " Effective Time "), scPharmaceuticals Inc. (the " Company ") terminated the Credit Agreement and Guaranty, dated as of August 9, 2024 (as amended, restated, supplemented or otherwise modified prior to the Effective Time, the " Existing Credit Agreement "), by and among the Company, the subsidiary guarantors from time to time party thereto, the lenders party thereto and Perceptive Credit Holdings IV, LP, as administrative agents for the lenders.

Quoted from scPharmaceuticals Inc.'s Form 8-K.

This is the only completed acquisition MannKind Corporation reported under Item 2.01 in the last twelve months, as far as the filings of the companies it bought show.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

All recent acquisitions